Epizyme Beats Out the Market With FDA Approval
Epizyme survived the market carnage of Monday morning’s trading session. In fact this biopharma came out of the fray better off than when it went in.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 251HMS Runs on State of New York Contract
ThinkstockHMS Holdings Corp. (NASDAQ: HMSY) is winning in the market Monday despite all the turmoil and volatility that tanked the market earlier. Only recently did this company reported earnings at the tail end of…
FDA Grants Expanded Use of Promacta for Novartis
ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss drug giant…
How Relevant is Vital Therapies After Its Selloff?
ThinkstockVital Therapies Inc. (NASDAQ: VTL) was last seen trading down 80% at $3.41 (versus $17.68 close) after it said that its Phase 3 trial in AILD (alcohol-induced liver decompensation) failed. Vital Therapies was downgraded…
Pfizer Gets Approval For Hospira Acquisition
ThinkstockAt a time when there is pressure on how large US companies are making domestic or overseas acquisitions are coming under more scrutiny, Pfizer Inc. (NYSE:PFE) announced on Monday that the Federal Trade Commission…
What Lit a Fire Under These 3 Pharma Stocks
Over the past week, a few pharmaceutical companies made absolutely massive runs.
Medequities Realty Trust Files for IPO
Medequities Realty Trust has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.
Eli Lilly Continues to Rise on Positive Jardiance Results
Eli Lilly shares got a solid boost in the market Thursday morning as the broad markets were selling off.
Applied Genetic Solidifies Deal With Biogen
Applied Genetic Technologies announced that the Biogen equity investment as part of their collaboration has closed.
Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks
ThinkstockWith biotech and specialty pharmaceutical stocks, catalysts and binary events can drive the stocks much higher, or in some cases much lower if the outcome is not what Wall Street was looking for. A…
Is Valeant About to Buy Maker of Female Viagra?
The Wall Street Journal reported Thursday morning that Canada-based Valeant Pharmaceuticals is preparing to pay $1 billion for the closely held Sprout Pharmaceuticals.
How a Fast Track Designation Saved Corbus Pharma
Corbus Pharmaceuticals may have found its saving grace in a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Will Sprout Pharmaceuticals Go Public?
Privately held start-up Sprout Pharmaceuticals received FDA approval on Tuesday for its flibanserin pill with the trade name Addyi.
Omeros Shares Doubling on Positive Phase 2 Data
ThinkstockOmeros Corp. (NASDAQ: OMER) is flying high in Tuesday’s trading session with shares practically doubling on positive phase 2 news. The company announced additional positive data in the it’s phase 2 clinical trial of…
Esperion Updates Phase 2 Study and Keeps Volatility Traders Interested
ThinkstockEsperion Therapeutics, Inc. (NASDAQ: ESPR) had a huge move in Monday’s trading session as the result of an analyst upgrade but it looks like this company has kept the rally alive into Tuesday with…